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SCIENTIFIC APPROACH TO MIGRAINE
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Summary
Migraine is a common episodic headache disorder; prevalence of migraine in most 
western countries is 10-12%. The mechanism of migraine pain development is not fully 
understood. The theory of neurogenic inflammation proposes that the main event is 
the inflammation in the vessel wall which leads to leakage of nociceptive substances, 
causing thickening of the vessel wall and dilatation of vascular smooth muscles. The 
release of vasoactive neuropeptides causes depolarization of trigeminal perivascular 
axons, thus causing pain. Triptans are recommended for acute migraine attacks; studies 
have shown that their use increases productivity at work and improves the quality of 
life. Preventive therapy is recommended in migraine patients with frequent, severe, 
long-lasting attacks, in cases where acute therapy is not efficient, if there is a contraindi-
cation to the drug, failure or unbearable side-effects from acute treatments, overuse of 
acute medications or in special cases such as hemiplegic migraine. Beta-blockers and 
tricyclic antidepressants were often used as first line therapy for migraine prevention. 
Other p reventive drugs include pizotifen, flunarizine, and anticonvulsives. Migraine is 
often associated with a number of commorbid diseases: allergies, hypotension, epilepsy, 
fatigue sy, gastritis, iritabile colon disease, vertigo; therefore, preventive and acute the-
rapy should be tailored individually.  
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Prevalence of migraine
Migraine is a common episodic headache disorder. Population-based epide-
miological studies about headaches especially migraine, have been carried out 
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in many countries. In western European countries and in the USA the prevalen-
ce of migraine is 10-12% (15-18% in women and 6% in men) [1,2]. The prevalence 
of migraine is higher in North America and Europe and lower in Africa and 
Asia [1]. Prevalence of migraine is consistently higher among women than men 
and varies from 1.5% to 33% in women and from 0.6% to 22% in men [1,2].
Studies show differences in prevalence of migraine between countries, even 
in the same country, which is most due to methodology of data collection. Majo-
rity of epidemiological studies were undertaken before the second edition of the 
International Classification of Headache Disorders (ICHD-2) [3] and assessed 
the prevalence of „strict migraine“. Since clinical and epidemiological studies 
show that a proportion of the studied population does not fulfill all criteria for 
migraine but clinically most likely have migraine, a subgroup of „probable mi-
graine“ was introduced. Some studies published before the ICHD-2 criteria have 
classified migraine that does not fulfill all criteria for migraine as „border-line 
migraine“ [4] and other as „probable migraine“[5,6].
We have also conducted an epidemiological survey in Croatia; the aims of 
this study were to assess the 1-year prevalence of migraine, probable migraine 
and tension-type headache in the Croatian population. The design of the study 
was a cross-sectional survey of an adult population sample using a self-com-
pleted questionnaire. The results of our study have shown that the 1-year pre-
valence of migraine in this study was 6.22% (women 8.3%, men 4.0%), probable 
migraine 8.78% (women 12.39%, men 5.0%) and tension-type headache 20.65% 
(women 23.8%, men 17.1%). The prevalence of combined migraine and probable 
migraine was 15.0% (women 20.6%, men 9.0%). Prevalence of migraine with aura 
was 2.5%. Total prevalence of headache (combined migraine, probable migraine 
and tension-type headache) was 35.65% (women 44.4%, men 26.1%). Prevalence 
of migraine was higher in continental than in Mediterranean areas of Croatia. 
We concluded that the prevalence of migraine and probable migraine is similar 
as in other Western countries. Certain demographic characteristics differ among 
patients with and without headache.  Some studies have shown higher preva-
lence of migraine among people with high education level [7], while others have 
not [8,9]. Most studies have not shown a correlation between marital status and 
migraine, in one study more migraine patients were married, while other study 
showed greater prevalence of migraine in divorced and widowed [10,11]. One 
study showed no correlation of migraine and employment status, although re-
tired had less migraine, the same study showed higher prevalence of migrai-
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ne among employed. Higher migraine prevalence among urban areas has been 
shown in two studies [11,12]. 
PathoPhysiology of migraine
The mechanism of migraine pain development is not fully understood. The 
theory of neurogenic inflammation proposes that the main event is the infla-
mmation in the vessel wall which leads to leakage of nociceptive substances, 
causing thickening of the vessel wall and dilatation of vascular smooth muscles. 
The release of vasoactive neuropeptides causes depolarization of trigeminal pe-
rivascular axons, thus causing pain [13].  Epidemiological studies regarding the 
vessel lumen diameter and studies including changes of cerebral hemodynami-
cs and vasoreactivity during migraine attack and in free periods  contribute to 
the understanding of migraine pathomechanism [14-17]. 
There is a longstanding belief that hereditary factors are involved in migra-
ine, this view is supported by the results of recent genetic mapping studies. Mi-
graine is a polygenic multifactorial disorder; it seems likely that a combination 
of genetic factors interact with enviromental triggers to produce migraine in 
susceptible patients. Genetic factors likely account for 30% of the risk, with en-
vironmental factors contributing 70% of the risk). A gene for familial hemiplegic 
migraine has been mapped to chromosome 19 in most families. The genetics of 
the more frequent variants, migraine with and without aura, is more complex 
[17].
Evidence from other studies supports the view that PM is a form of migra-
ine. A genetic study showed that PM and migraine without aura aggregate in 
some families [18]. If PM is a prevalent form of migraine, population studies 
focusing on strict migraine (ICHD-2 1.1 and 1.2) may underestimate the signifi-
cance and impact of migraine. Therefore, diagnosis of PM in clinical practice is 
an important issue.
Diagnosis of migraine
There are, as yet, no tests that confirm the diagnosis of migraine [19-21]. The 
headache diary is the most important diagnostic tool  and should be filled in 
for at least 3 months in which frequency, duration and intensity of migraine 
attacks are registered. The total number of  hours with headache per month, pre-
sence of accompanying symptoms, the use of symptomatic therapy should be 
listed. Selective testing, including neuroimaging (computed tomography [CT] or 
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magnetic resonance imaging [MRI]), electroencephalogram, lumbar puncture, 
cerebrospinal fluid and blood studies, may be indicated to evaluate for secon-
dary headache if causes of concern have been identified in the patient history or 
physical examination. Diagnosis may be complicated if several headache types 
coexist in the same patient. Neuroimaging is not usualy warranted for patients 
with migraine and normal neurological examination. For patients with atypical 
headache features or patients who do not fulfill the strict definition of migraine 
(or have some additional risk factors), a lower threshold for neuroimaging may 
be applied. 
theraPy of migraine
Preventive therapy is recommended in migraine patients with frequent, se-
vere, long-lasting attacks, in cases where acute therapy is not efficient, if there 
is a contraindication to the drug, failure or unbearable side-effects from acute 
treatments, overuse of acute medications or in special cases such as hemiplegic 
migraine. Treatment should be selected on individual basis taking into conside-
ration co-morbidities, efficacy of the drug, adverse reactions, patient preference, 
availability and costs [20-25]. Prophylactic therapy for migraine should be based 
on guidelines from evidence-based medicine. Although double-blind placebo 
controlled studies provide un-biased results, they are sometimes difficult to 
carry out, therefore open-label studies offer additional data on the efficacy of 
pharmacological or non-pharmacological treatment. The chosen drug should be 
started in low dose and gradually increased, and should be given an adequate 
trial (at least three months).  
Medications used in migraine prophylaxis come from different pharmaco-
logical classes and most have primary indications for other medical conditions 
[21,23,25]. Beta-blockers and tricyclic antidepressants were often used as first 
line therapy for migraine prevention. Other preventive drugs include pizotifen, 
flunarizine, and methysergid [26]. 
However, in some patients, in whom these medications are contraindicated, 
or who have comorbid diseases, antiepileptic drugs (AEDs) may be offered as an 
appropriate first-line prophylactic treatment. Trials with AEDs as prophylactic 
drugs in migraine have shown that certain AEDs can be offered in patients re-
fractory to usual prophylactic treatment. 
Valproate was the first AED recommended for migraine prevention. Divalpro-
ex sodium and sodium valproate (300-900 mg) in controlled studies have shown 
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consistent efficacy in reducing headache frequency compared with placebo [27,28]; 
compared with propranolol there was no significant difference in efficacy [29].
Several double blind placebo controlled studies have shown that topiramate 
is effective in migraine prophylaxis: one study showed a mean 28-day migraine 
frequency reduction by 36% in patients receiving topiramate vs 14% in placebo 
group; 26%  achieved a 50% reduction in migraine frequency vs 9,5% in placebo 
group, 2 out of 19 topiramate treated patients discontinued treatment due to 
adverse events [30]. Topiramate was efficient in the prophylaxis of chronic mi-
graines: reduction of headache frequency > 50% was 58,3% in episodic migraine 
and in 38.0% in chronic migraine patients on topiramate up to 100 mg twice da-
ily; the mean headache severity was reduced from 6.2 to 4.8 on a 10-point scale, 
both results significant [31]. A double-blind, crossover clinical trial compared 
the efficacy of topiramate and sodium valproate in migraine prevention and the 
two drugs appear to be equivalent in efficacy and safety; a significant decrease 
in duration, monthly frequency and intensity of headache occurred in both gro-
ups: in valproate group the mean monthly frequency decreased from 5.4 to 4.0 
and in topiramate group from 5.4 to 3.2 and headache intensity from 7.7 to 5.8 
and from 6.9 to 3.7, respectively [32]. 
Gabapentin is among AEDs that has been evaluated for its effectiveness in 
migraine prevention [33-35]. In a 12-week open-label study gabapentin in dosage 
of 600-1800 mg was effective in episodic and chronic migraine, headache frequ-
ency decreased from 25.2 to 11.6 per month, side effects in this study were mini-
mal [33]. A placebo controlled study with 98 patients receiving gabapentin and 
45 placebo showed that gabapentin in dosage of 1800-2400 was effective in redu-
cing the frequency of migraine attacks: the responder rate (50% decrease in attack 
frequency) was 46,4% in the gabapentin group and 16,1% in placebo; furthermore 
a 4-week  migraine headache rate decreased from 4.2 to 2.7 in gabapentin gro-
up and from 4.1 to 3.5 in placebo group which was significant [34]. Lamotrigine 
has shown to be efficient in prophylaxis of migraine with aura. Three open label 
studies showed that lamotrigine reduces the number of migraine auras and the 
frequency of migraine attacks. In 13 out of  21  patients receiving lamotrigine 100 
mg attacks were completely abolished and one patients was unresponsive to the 
treatment at the end of the third month [36]. In other two studies lamotrigine 
significantly reduced the number of migraine auras (from 4.2 to 0.7) [37], the du-
ration of the migraine auras and the frequency of migraine attacks [38]. 
For acute attacks, triptans are widely recommended for migraine since stu-
dies have shown that their use increases productivity at work and improves 
the quality of life of migraine sufferers [39]. However, studies worldwide show 
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that the majority of migraine patients are using OTCs and the minority is using 
triptans [40-43]. Most studies worldwide show that in general population trip-
tans are taking 3-19% of patients with migraine, while most patients are taking 
simple analgesics [40-43]. In some countries, higher percentages of triptan use 
have been observed, as 48.7% in Canada (44). Preventive treatment uses a low 
percentage of migraine patients, studies show a range from 6-12.4% [41,45]. 
Studies continuously show low rates of medical consultations in patients 
with headache, even in those patients who are aware of their condition [40,45]. A 
large number of migraine patients have no medical follow-up for their conditi-
on, and think that consultations are useless and that there is no cure for migrai-
ne [41]. Many migraine sufferers who do consult physicians for migraine do not 
receive a correct diagnosis. In a US study, 40% of migraine sufferers stated that 
they have not been told as having migraine even after consultation with a physi-
cian [46]. In another US study only 45 % of migraineurs who consulted for hea-
daches were correctly diagnosed [47]. Many migraine patients who do consult 
their physicians find that their prescribed acute medications provide inadequate 
relief. In a population-based study in United States, only 29% of migraineurs 
reported that they were “very satisfied” with their usual acute treatment [48]. 
commorbiD Diseases
Migraine is often associated with a number of commorbid diseases: allergies, 
hypotension, epilepsy, fatigue sy, gastritis, iritabile colon disease, vertigo. Vertigo 
has been found to be three times more common in migraine patients than in the 
control group: vertigo occurred in 24-27% of migraine patients compared with 
controls (8-10%) [49,50]. Studies show that among patients with migrainous ver-
tigo, vertigo was regularly associated with migrainous headache by 24% to 45%; 
[51,52]. Similar findings have been shown in other studies [49,53] as well as in a 
study performed at the Headache clinic at the Department of Neurology Sestre 
milosrdnice University Hospital: vertigo symptoms were associated with a migra-
ine attack always in 38 (22.5%), sometimes in 38 (22.5%) and were not associated in 
93 (55.0%). This means that the lifetime prevalence of migrainous vertigo is 23.2% 
in the population of our migraineurs according to the proposed criteria [54].  
Migraine and probable migraine are associated with substantial disability 
measured by decrement in health related quality of life (HRQoL) and MIDAS 
score. Migraine causes significant burden for both the individual and society. 
Calculations of direct costs generally include physician visits, emergency de-
partment treatment, inpatient care and pharmacotherapy. Indirect costs include 
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lost work days and reduced performance at work; two-thirds of the financial 
burden is linked to indirect costs. Approximately ¾ of migraine sufferers have a 
reduced ability to function during attacks with more than half reporting severe 
disability or need for bed rest. Therefore, the diagnosis and treatment of  migra-
ine should be improved. 
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Migrena je česta glavobolja čija se prevalencija kreće u zapadnim zemljama između 10-
12%. Mehanizam boli kod migrene nije sasvim razjašnjen. Po teoriji neurogene upale  glav-
no zbivanje je upala stijenki krvnih žila koja dovodi do istjecanja nociceptivnih supstanci što 
uzrokuje zadebljanje zida arterija te dilataciju glatkih mišićnih stanica. Otpuštanje vazoaktivnih 
neuropeptida uzrokuje depolarizaciju trigeminalnih aksona što dovodi do pojave boli. Triptani se 
preporučaju u akutnim napadajima migrene; istraživanja su pokazala da se njihovom upotrebom 
u akutnom napadaju migrene povećava produktivnost na poslu i poboljšava kvaliteta života. 
Preventivna terapija se preporuča kod osoba s učestalim jakim i dugotrajnim napadajima, te u 
slučajevima kada akutna terapija nije učinkovita, ukoliko postoji kontraindikacija ili su izražene 
nuspojave za primjenu akutne terapije, te u slučajevima kada se radi o obiteljskoj hemiplegij-
skoj  migreni. U preventivnoj terapiji preporučaju se beta blokatori i triciklički antidepresivi a od 
ostalih lijekova se preporučaju pizotifen, flunarizin te antiepileptici. Migrena je često udružena 
s komorbidnim bolestima poput alergija, hipotenzije, epilepsija, sindromom kroničnog umora, 
iritabilnim kolonom, gastritisom i vertigom; stoga se akutna i profilaktička terapija moraju indi-
vidualno određivati. 
Ključne riječi: migrena; patofiziologija; dijagnoza; terapija.
